Publicacións nas que colabora con Mercedes Delgado Valverde (9)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

2023

  1. Corrigendum: CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3(Front. Microbiol., (2022), 13, (918362), 10.3389/fmicb.2022.918362)

    Frontiers in Microbiology

2022

  1. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

    Frontiers in Microbiology, Vol. 13

  2. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

    Microbiology spectrum, Vol. 10, Núm. 5, pp. e0292722

  3. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 11, pp. 3163-3172

2021

  1. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 2, pp. 370-379

2020

  1. Mechanisms of tolerance and resistance to chlorhexidine in clinical strains of Klebsiella pneumoniae producers of carbapenemase: Role of new type II toxin-antitoxin system, PemIK

    Toxins, Vol. 12, Núm. 9

  2. WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 4

2017

  1. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: Discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 5, pp. 1478-1487